← back to search

Nicholas J. Wang

Lawrence Berkeley National Laboratory · US
Area of research
Cancer Research · Oncology
Research interest
Research interests include Cancer Cells and Metastasis, Cancer Genomics and Diagnostics, Breast Cancer Treatment Studies, and HER2/EGFR in Cancer Research.
h-index
29
citations
6,276
works
137
NIH funding
primary concept
email

Recent publications

Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer
Nature Communications 2018cited by 181position: middledoi
Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer
Breast Cancer Research 2017cited by 2position: middledoi
Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer
Breast Cancer Research 2016cited by 38position: middledoi
Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway
Nature Genetics 2015cited by 286position: middledoi
Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination
Proceedings of the National Academy of Sciences 2015cited by 193position: middledoi
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
Clinical Cancer Research 2015cited by 119position: middledoi
Erratum to: Modeling precision treatment of breast cancer
Genome Biology 2015cited by 11position: middledoi
A community effort to assess and improve drug sensitivity prediction algorithms
Nature Biotechnology 2014cited by 824position: middledoi
Transcription Restores DNA Repair to Heterochromatin, Determining Regional Mutation Rates in Cancer Genomes
Cell Reports 2014cited by 124position: middledoi
Modeling precision treatment of breast cancer
Genome biology 2013cited by 317position: middledoi
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
Breast Cancer Research and Treatment 2012cited by 74position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Joe W. Gray · Directorate-General for Interpretation8 papers (2012–2018)Paul T. Spellman · University of California System5 papers (2012–2018)Laura M. Heiser · Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie4 papers (2014–2017)James E. Korkola · Oregon Health & Science University3 papers (2012–2017) · 2 papers (2016–2017) · 2 papers (2016–2017) · 2 papers (2016–2017)Shamith Samarajiwa · Imperial College London2 papers (2016–2017)José A. Seoane · Hebron University2 papers (2016–2017) · 2 papers (2015–2015)Klaus J. Busam · Memorial Sloan Kettering Cancer Center2 papers (2015–2015)Heidi S. Feiler · Oregon Health & Science University2 papers (2016–2017) · 2 papers (2016–2017)John F. Thompson · Kaiser Permanente Center for Health Research2 papers (2015–2015) · 2 papers (2016–2017)Raymond J. Cho · University of California, San Francisco2 papers (2015–2015)Rajmohan Murali · Faculty of Media2 papers (2015–2015)Boris C. Bastian · University of California, San Francisco2 papers (2015–2015)Mark Dane · Oregon Health & Science University2 papers (2016–2017) · 2 papers (2015–2015)